• ResMed's Oct. 29, 2026, Q1 fiscal 2027 earnings call featured CEO Michael J. Farrell, CFO Aaron Bloomer and investor-relations chief Sallilyn Schwartz.
• Quarterly revenue reached $1.4 billion; non-GAAP diluted earnings per share rose 14% to $2.91.
• Management maintained full-year revenue guidance of $5.75 billion-$5.85 billion; non-GAAP earnings per share remain projected at $12-$12.25.
• Core constant-currency revenue growth guidance remains 5%-7%, with Bloomer calling the midpoint most likely as France's fleet-renewal benefit fades.
• Non-GAAP gross margin reached 62.5%; deferred Indiana expansion costs create an expected 30-basis-point sequential headwind in Q2.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.